NASDAQ:VSAR - Versartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.19 -0.02 (-1.65 %)
(As of 02/17/2019 10:33 AM ET)
Previous Close$1.19
Today's Range$1.1802 - $1.30
52-Week Range$1.14 - $2.76
Volume349,963 shs
Average Volume479,436 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VSAR
CUSIPN/A
Phone650-963-8580

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees10
OptionableOptionable

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.69. View Versartis' Earnings History.

What price target have analysts set for VSAR?

1 analysts have issued 1 year target prices for Versartis' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Versartis' share price to reach $5.00 in the next year. This suggests a possible upside of 320.2% from the stock's current price. View Analyst Price Targets for Versartis.

What is the consensus analysts' recommendation for Versartis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Versartis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Versartis.

Has Versartis been receiving favorable news coverage?

News coverage about VSAR stock has trended negative on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Versartis earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 60)
  • Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. (Age 53)

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $1.19.

What is Versartis' official website?

The official website for Versartis is http://www.versartis.com.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (NASDAQ VSAR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel